Latest Deals

23andMe has been flagging in recent years, due in part to its inability to articulate a sound business model. Credit: Jennie Book / Shutterstock

A court has approved the $305m sale of 23andMe’s assets to a nonprofit led by its former CEO Anne Wojcicki, effectively putting her back in control of the bankrupt genetics company. Under the sale, TTAM will acquire all 23andMe’s assets, including its Personal Genome Service (PGS) and Research Services business lines, as well as Lemonaid Health business. 

Canadian company Kardium has raised C$340m ($250m) to support the launch of its Globe pulsed field (PF) system for treating atrial fibrillation (AFib). The latest fund raise brings the company’s total capital to $425m and was led by new investors, including Janus Henderson Investors and Eckuity Capital. Existing investors such as T Rowe Price Investment Management and Durable Capital Partners also participated. 

Field Medical has closed a $35m Series B financing round for advancing the development of the FieldForce pulsed field ablation platform. This round was co-led by BioStar Capital and Cue Growth, with contributions from current strategic investors. The funds will also facilitate the launch of the pivotal VERITAS trial and strengthen the company’s clinical and regulatory capabilities. 

Israel-based ForSight Robotics has completed a Series B funding round, raising $125m to fuel the growth phase of the robotic surgery platform intended for cataract and other eye conditions. Claimed to be a world first, the ORYOM platform is tailored to reduce the physical load on surgeons and improve surgical precision.